For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240509:nRSI8512Na&default-theme=true
RNS Number : 8512N Uniphar PLC 09 May 2024
AGM Results
Dublin, London | 9 May 2024
Uniphar plc (the Company) is pleased to announce that at its Annual General
Meeting held at 11.00 a.m. today, 9 May 2024, each of the resolutions set out
in the Notice of Annual General Meeting circulated to shareholders and made
available on the Company's website, www.uniphar.ie (http://www.uniphar.ie) ,
were duly passed without amendment.
Details of votes cast are set out below:
RESOLUTION For For % Against Against Withheld
%
1 Financial Statements and Reports 142,776,909 100 - 0 1,659,778
2 Final Dividend of €3.2m 144,436,687 100 - 0 -
3(a) Re-elect Ger Rabbette 133,691,402 92.56 10,745,283 7.44 2
3(b) Re-elect Tim Dolphin 143,757,800 99.53 678,887 0.47 -
3(c) Re-elect Paul Hogan 143,473,422 99.35 938,265 0.65 25,000
3(d) Re-elect Sue Webb 144,049,623 99.77 333,788 0.23 53,276
3(e) Re-elect Jim Gaul 138,288,164 95.78 6,095,247 4.22 53,276
3(f) Re-elect Liz Hoctor 144,320,340 99.94 91,347 0.06 25,000
3(g) Re-elect Maurice Pratt 141,968,268 98.29 2,468,417 1.71 2
3(h) Re-elect Valerie Sick 144,143,411 99.83 240,000 0.17 53,276
4 Remuneration of Auditors 119,304,023 95.49 5,630,519 4.51 19,502,145
5 Authority to allot relevant securities 125,835,071 87.14 18,573,338 12.86 28,278
6 Disapplication of pre-emption rights in specified circumstances 143,264,607 99.19 1,172,080 0.81 -
7 Disapplication of pre-emption rights in additional circumstances 119,856,072 83.18 24,242,889 16.82 337,726
8 Authorise market purchases of the Company's Ordinary Shares 143,853,843 100 - 0 582,844
9 Re-issuance of Treasury Shares 142,676,687 98.78 1,760,000 1.22 -
--- ENDS ---
Contact Details
Uniphar Group Tel: +353 (0) 1 428 7777
Allan Smylie, Head of Strategy and IR
Davy (Joint Corporate Broker, Nominated Advisor and Tel: +353 (0) 1 679 6363
Euronext Growth Listing Sponsor)
Daragh O'Reilly
Niall Gilchrist
Ivan Murphy
RBC Capital Markets (Joint Corporate Broker) Tel: +44 (0) 20 7653 4000
Jamil Miah
Rupert Walford
Stifel Nicolaus Europe Limited (Joint Corporate Broker) Tel: +44 (0) 20 7710 7600
Matt Blawat
Ben Maddison
Francis North
Q4 PR Tel: +353 (0) 1 475 1444
Iarla Mongey, Public Relations Advisor to Uniphar Group
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply
Chain & Retail. The Group is active in Europe, North America, APAC and
MENA and delivers to 160+ countries.
The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in
Ireland with a growing symbol group offering of retail pharmacies. The Group's
strategy for Uniphar Supply Chain & Retail is to grow our wholesale market
share, our symbol group network and our own brand, in-licenced and consumer
products portfolio.
Uniphar Medtech
Uniphar Medtech is a leading Pan-European medical device distributor and
solutions partner. The Group's strategy for Uniphar Medtech is to grow our
service offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the
lifecycle of a pharmaceutical product. We enable pharma and biotech companies
to bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they can't source through traditional
channels. Our strategy is to build a leading platform to provide the
specialist support and expertise needed to improve access to these medicines.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGQKCBBNBKDQPK